- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
August 16th, 2007
By Jack Uldrich August 16, 2007
While reading an interesting article about the link between academic research and commercial products, I stumbled upon an intriguing company experimenting with a novel -- and tiny -- new way to fight cancer.
Insert Therapeutics, a subsidiary of Arrowhead Research (Nasdaq: ARWR), specializes in developing promising nanotechnology-related university research. It seems that Insert Therapeutics is focusing on an innovative new nanotech-based platform for the treatment of cancer, and it's helping to shepherd the platform through the FDA clinical phase process. The drug in question is only in phase 1 of FDA trials, so it still has a long way to go, and there's absolutely no guarantee that it will ever receive final approval.
|Related News Press|
Forge Nano raises $20 million in Series A Funding: Nano coating technology innovator Forge Nano will use funding to expand manufacturing capacity and grow Lithium-Ion battery opportunities November 3rd, 2016
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers
Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016